These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33959697)

  • 1. mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development.
    Ilyichev AA; Orlova LA; Sharabrin SV; Karpenko LI
    Vavilovskii Zhurnal Genet Selektsii; 2020 Nov; 24(7):802-807. PubMed ID: 33959697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use.
    Vasireddy D; Atluri P; Malayala SV; Vanaparthy R; Mohan G
    J Clin Med Res; 2021 Apr; 13(4):204-213. PubMed ID: 34007358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
    Choi JA; Goo J; Yang E; Jung DI; Lee S; Rho S; Jeong Y; Park YS; Park H; Moon YH; Park U; Seo SH; Lee H; Lee JM; Cho NH; Song M; Kim JO
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2.
    Baldo A; Leunda A; Willemarck N; Pauwels K
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34063733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight.
    He C; Qin M; Sun X
    Acta Pharm Sin B; 2020 Jul; 10(7):1175-1191. PubMed ID: 32834948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivating Three Interferon Antagonists Attenuates Pathogenesis of an Enteric Coronavirus.
    Deng X; Buckley AC; Pillatzki A; Lager KM; Faaberg KS; Baker SC
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32554697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Zhang C; Zhou C; Shi L; Liu G
    Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines against Coronaviruses: The State of the Art.
    Conte C; Sogni F; Affanni P; Veronesi L; Argentiero A; Esposito S
    Vaccines (Basel); 2020 Jun; 8(2):. PubMed ID: 32560340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination.
    Tombácz I; Weissman D; Pardi N
    Methods Mol Biol; 2021; 2197():13-31. PubMed ID: 32827130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS - CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis).
    Ietto G
    Med Hypotheses; 2020 Aug; 141():109779. PubMed ID: 32387756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Principles and new perspectives in the vaccination against SARS-CoV-2 virus.
    Smetanová J; Střížová Z; Bartůňková J; Milota T
    Cas Lek Cesk; 2020; 159(7-8):298-302. PubMed ID: 33445936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA vaccines: the most recent clinical applications of synthetic mRNA.
    Kwon S; Kwon M; Im S; Lee K; Lee H
    Arch Pharm Res; 2022 Apr; 45(4):245-262. PubMed ID: 35426547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
    Yu J; Tostanoski LH; Peter L; Mercado NB; McMahan K; Mahrokhian SH; Nkolola JP; Liu J; Li Z; Chandrashekar A; Martinez DR; Loos C; Atyeo C; Fischinger S; Burke JS; Slein MD; Chen Y; Zuiani A; Lelis FJN; Travers M; Habibi S; Pessaint L; Van Ry A; Blade K; Brown R; Cook A; Finneyfrock B; Dodson A; Teow E; Velasco J; Zahn R; Wegmann F; Bondzie EA; Dagotto G; Gebre MS; He X; Jacob-Dolan C; Kirilova M; Kordana N; Lin Z; Maxfield LF; Nampanya F; Nityanandam R; Ventura JD; Wan H; Cai Y; Chen B; Schmidt AG; Wesemann DR; Baric RS; Alter G; Andersen H; Lewis MG; Barouch DH
    Science; 2020 Aug; 369(6505):806-811. PubMed ID: 32434945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targets and strategies for vaccine development against SARS-CoV-2.
    Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
    Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.